Literature DB >> 8684165

Use of CA 125 in follow-up of ovarian cancer.

G Rustin, M Tuxen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8684165     DOI： 10.1016/s0140-6736(05)66133-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment.

Authors:  Fiona Kew; Khadra Galaal; Andrew Bryant; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

2.  Extracellular Vesicles Contain Putative Cancer Biomarkers.

Authors:  Sai V Chitti; Christina Nedeva
Journal:  Subcell Biochem       Date:  2021

3.  Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?

Authors:  Ahmet Bilici; Bala Basak Oven Ustaalioglu; Mesut Seker; Nesrin Canpolat; Bulent Tekinsoy; Taflan Salepci; Mahmut Gumus
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

4.  Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Domeki; Yasushi Kaji; Ichio Fukasawa; Noriyuki Inaba; Narufumi Suganuma; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

5.  Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.

Authors:  Katrin M Sjoquist; Michael L Friedlander; Rachel L O'Connell; Merryn Voysey; Madeleine T King; Martin R Stockler; Amit M Oza; Kim Gillies; Julie K Martyn; Phyllis N Butow
Journal:  Oncologist       Date:  2013-10-09

6.  C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis.

Authors:  Qi Liu; Zhen Cheng; Lianzhong Luo; Yun Yang; Zhenzhu Zhang; Huanhuan Ma; Tao Chen; Xi Huang; Shu-Yong Lin; Meijun Jin; Qinxi Li; Xiaotong Li
Journal:  Oncotarget       Date:  2016-06-14

Review 7.  MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

Authors:  Mildred Felder; Arvinder Kapur; Jesus Gonzalez-Bosquet; Sachi Horibata; Joseph Heintz; Ralph Albrecht; Lucas Fass; Justanjyot Kaur; Kevin Hu; Hadi Shojaei; Rebecca J Whelan; Manish S Patankar
Journal:  Mol Cancer       Date:  2014-05-29       Impact factor: 27.401
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.